A Randomized Double-Blind Placebo-Controlled Trial of Dipeptidyl Peptidase-1 Inhibition in Hospitalized Patients with COVID-19: The STOP-COVID19 Trial

H. R. Keir; M. B. Long; H. Abo leyah; Y. H. Giam; T. Vadiveloo; T. Pembridge; R. Hull; L. Delgado; M. Band; F. Mclaren-Neill; S. Adamson; E. Lahnsteiner; A. Gilmour; C. Hughes; B. J. M. New; D. Connell; R. Dowey; H. Turton; H. Richardson; D. Cassidy; J. Cooper; J. Suntharalingam; L. Diwakar; P. Russell; J. Underwood; A. Hicks; D. P. Dosanjh; E. Sage; D. Dhasmana; M. Spears; R. Thompson; C. Brightling; M. Patel; J. George; A. M. Condliffe; A. Shoemark; G. Maclennan; J. D. Chalmers

doi:10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A5055

A Randomized Double-Blind Placebo-Controlled Trial of Dipeptidyl Peptidase-1 Inhibition in Hospitalized Patients with COVID-19: The STOP-COVID19 Trial

H. R. Keir (Lead / Corresponding author), M. B. Long, H. Abo leyah, Y. H. Giam, T. Vadiveloo, T. Pembridge, R. Hull, L. Delgado, M. Band, F. Mclaren-Neill, S. Adamson, E. Lahnsteiner, A. Gilmour, C. Hughes, B. J. M. New, D. Connell, R. Dowey, H. Turton, H. Richardson, D. CassidyJ. Cooper, J. Suntharalingam, L. Diwakar, P. Russell, J. Underwood, A. Hicks, D. P. Dosanjh, E. Sage, D. Dhasmana, M. Spears, R. Thompson, C. Brightling, M. Patel, J. George, A. M. Condliffe, A. Shoemark, G. Maclennan, J. D. Chalmers

Research output: Contribution to conference › Paper › peer-review

Abstract

Rationale: Markers of neutrophilic inflammation, including neutrophil serine proteases, are increased in severe and fatal COVID-19 infection. We investigated whether treatment with Brensocatib, an oral inhibitor of Dipeptidyl Peptidase-1 (DPP1) which reduces neutrophilic inflammation, would improve clinical outcomes in hospitalized patients with COVID-19. Methods: A randomized, double-blind, placebo-controlled trial was conducted in 14 UK hospitals(ISRCTN30564012). Patients were randomized to receive Brensocatib (25mg/day) or placebo for28 days. Inclusion criteria required confirmed SARS-CoV-2 infection with at least one risk factor for severe disease (requirement for supplementary oxygen, oxygen saturation less than 94% on room air, radiographic infiltrates, evidence of pulmonary involvement in physical examination or lymphocyte count

Original language	English
Pages	A5055-A5055
Number of pages	1
DOIs	https://doi.org/10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A5055
Publication status	Published - 2 May 2022
Event	American Thoracic Society International Conference 2022 - San Francisco, United States Duration: 13 May 2022 → 18 May 2022 http://American Thoracic Society International Conference

Conference

Conference	American Thoracic Society International Conference 2022
Country/Territory	United States
City	San Francisco
Period	13/05/22 → 18/05/22
Internet address	http://American Thoracic Society International Conference

Access to Document

10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A5055

https://www.atsjournals.org/doi/10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A5055

Cite this

Keir, H. R., Long, M. B., Abo leyah, H., Giam, Y. H., Vadiveloo, T., Pembridge, T., Hull, R., Delgado, L., Band, M., Mclaren-Neill, F., Adamson, S., Lahnsteiner, E., Gilmour, A., Hughes, C., New, B. J. M., Connell, D., Dowey, R., Turton, H., Richardson, H., ... Chalmers, J. D. (2022). A Randomized Double-Blind Placebo-Controlled Trial of Dipeptidyl Peptidase-1 Inhibition in Hospitalized Patients with COVID-19: The STOP-COVID19 Trial. A5055-A5055. Paper presented at American Thoracic Society International Conference 2022, San Francisco, California, United States. https://doi.org/10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A5055

@conference{08025f364d214f9fae2b5f1ce981e9e1,

title = "A Randomized Double-Blind Placebo-Controlled Trial of Dipeptidyl Peptidase-1 Inhibition in Hospitalized Patients with COVID-19: The STOP-COVID19 Trial",

abstract = "Rationale: Markers of neutrophilic inflammation, including neutrophil serine proteases, are increased in severe and fatal COVID-19 infection. We investigated whether treatment with Brensocatib, an oral inhibitor of Dipeptidyl Peptidase-1 (DPP1) which reduces neutrophilic inflammation, would improve clinical outcomes in hospitalized patients with COVID-19. Methods: A randomized, double-blind, placebo-controlled trial was conducted in 14 UK hospitals(ISRCTN30564012). Patients were randomized to receive Brensocatib (25mg/day) or placebo for28 days. Inclusion criteria required confirmed SARS-CoV-2 infection with at least one risk factor for severe disease (requirement for supplementary oxygen, oxygen saturation less than 94% on room air, radiographic infiltrates, evidence of pulmonary involvement in physical examination or lymphocyte count ",

author = "Keir, {H. R.} and Long, {M. B.} and {Abo leyah}, H. and Giam, {Y. H.} and T. Vadiveloo and T. Pembridge and R. Hull and L. Delgado and M. Band and F. Mclaren-Neill and S. Adamson and E. Lahnsteiner and A. Gilmour and C. Hughes and New, {B. J. M.} and D. Connell and R. Dowey and H. Turton and H. Richardson and D. Cassidy and J. Cooper and J. Suntharalingam and L. Diwakar and P. Russell and J. Underwood and A. Hicks and Dosanjh, {D. P.} and E. Sage and D. Dhasmana and M. Spears and R. Thompson and C. Brightling and M. Patel and J. George and Condliffe, {A. M.} and A. Shoemark and G. Maclennan and Chalmers, {J. D.}",

year = "2022",

month = may,

day = "2",

doi = "10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A5055",

language = "English",

pages = "A5055--A5055",

note = "American Thoracic Society International Conference 2022 ; Conference date: 13-05-2022 Through 18-05-2022",

url = "http://American Thoracic Society International Conference",

}

Keir, HR, Long, MB, Abo leyah, H, Giam, YH, Vadiveloo, T, Pembridge, T, Hull, R, Delgado, L, Band, M, Mclaren-Neill, F, Adamson, S, Lahnsteiner, E, Gilmour, A, Hughes, C , New, BJM , Connell, D, Dowey, R, Turton, H, Richardson, H, Cassidy, D, Cooper, J, Suntharalingam, J, Diwakar, L, Russell, P, Underwood, J, Hicks, A, Dosanjh, DP, Sage, E, Dhasmana, D, Spears, M, Thompson, R, Brightling, C, Patel, M, George, J, Condliffe, AM, Shoemark, A, Maclennan, G & Chalmers, JD 2022, 'A Randomized Double-Blind Placebo-Controlled Trial of Dipeptidyl Peptidase-1 Inhibition in Hospitalized Patients with COVID-19: The STOP-COVID19 Trial', Paper presented at American Thoracic Society International Conference 2022, San Francisco, United States, 13/05/22 - 18/05/22 pp. A5055-A5055. https://doi.org/10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A5055

A Randomized Double-Blind Placebo-Controlled Trial of Dipeptidyl Peptidase-1 Inhibition in Hospitalized Patients with COVID-19: The STOP-COVID19 Trial. / Keir, H. R. (Lead / Corresponding author); Long, M. B.; Abo leyah, H. et al.
2022. A5055-A5055 Paper presented at American Thoracic Society International Conference 2022, San Francisco, California, United States.

Research output: Contribution to conference › Paper › peer-review

TY - CONF

T1 - A Randomized Double-Blind Placebo-Controlled Trial of Dipeptidyl Peptidase-1 Inhibition in Hospitalized Patients with COVID-19

T2 - American Thoracic Society International Conference 2022

AU - Keir, H. R.

AU - Long, M. B.

AU - Abo leyah, H.

AU - Giam, Y. H.

AU - Vadiveloo, T.

AU - Pembridge, T.

AU - Hull, R.

AU - Delgado, L.

AU - Band, M.

AU - Mclaren-Neill, F.

AU - Adamson, S.

AU - Lahnsteiner, E.

AU - Gilmour, A.

AU - Hughes, C.

AU - New, B. J. M.

AU - Connell, D.

AU - Dowey, R.

AU - Turton, H.

AU - Richardson, H.

AU - Cassidy, D.

AU - Cooper, J.

AU - Suntharalingam, J.

AU - Diwakar, L.

AU - Russell, P.

AU - Underwood, J.

AU - Hicks, A.

AU - Dosanjh, D. P.

AU - Sage, E.

AU - Dhasmana, D.

AU - Spears, M.

AU - Thompson, R.

AU - Brightling, C.

AU - Patel, M.

AU - George, J.

AU - Condliffe, A. M.

AU - Shoemark, A.

AU - Maclennan, G.

AU - Chalmers, J. D.

PY - 2022/5/2

Y1 - 2022/5/2

N2 - Rationale: Markers of neutrophilic inflammation, including neutrophil serine proteases, are increased in severe and fatal COVID-19 infection. We investigated whether treatment with Brensocatib, an oral inhibitor of Dipeptidyl Peptidase-1 (DPP1) which reduces neutrophilic inflammation, would improve clinical outcomes in hospitalized patients with COVID-19. Methods: A randomized, double-blind, placebo-controlled trial was conducted in 14 UK hospitals(ISRCTN30564012). Patients were randomized to receive Brensocatib (25mg/day) or placebo for28 days. Inclusion criteria required confirmed SARS-CoV-2 infection with at least one risk factor for severe disease (requirement for supplementary oxygen, oxygen saturation less than 94% on room air, radiographic infiltrates, evidence of pulmonary involvement in physical examination or lymphocyte count

AB - Rationale: Markers of neutrophilic inflammation, including neutrophil serine proteases, are increased in severe and fatal COVID-19 infection. We investigated whether treatment with Brensocatib, an oral inhibitor of Dipeptidyl Peptidase-1 (DPP1) which reduces neutrophilic inflammation, would improve clinical outcomes in hospitalized patients with COVID-19. Methods: A randomized, double-blind, placebo-controlled trial was conducted in 14 UK hospitals(ISRCTN30564012). Patients were randomized to receive Brensocatib (25mg/day) or placebo for28 days. Inclusion criteria required confirmed SARS-CoV-2 infection with at least one risk factor for severe disease (requirement for supplementary oxygen, oxygen saturation less than 94% on room air, radiographic infiltrates, evidence of pulmonary involvement in physical examination or lymphocyte count

U2 - 10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A5055

DO - 10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A5055

M3 - Paper

SP - A5055-A5055

Y2 - 13 May 2022 through 18 May 2022

ER -

Keir HR, Long MB, Abo leyah H, Giam YH, Vadiveloo T, Pembridge T et al.. A Randomized Double-Blind Placebo-Controlled Trial of Dipeptidyl Peptidase-1 Inhibition in Hospitalized Patients with COVID-19: The STOP-COVID19 Trial. 2022. Paper presented at American Thoracic Society International Conference 2022, San Francisco, California, United States. doi: 10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A5055

A Randomized Double-Blind Placebo-Controlled Trial of Dipeptidyl Peptidase-1 Inhibition in Hospitalized Patients with COVID-19: The STOP-COVID19 Trial

Abstract

Conference

Access to Document

Fingerprint

Cite this